The size of the Middle East and Africa multiple myeloma therapeutics market was worth USD 733.18 Million in 2022 and estimated to be growing at a CAGR of 4.74%, to reach USD 924.22 Million by 2027.
The MEA multiple myeloma therapeutics market is projected to grow due to various reasons, including the rapid increase in the aging population, rising healthcare costs, and the development of inaccurate diagnostic tests and treatment modalities. Owing to the extensive research and development taking place in oncology, the following line of drugs for multiple myeloma has shown promising results, with biologic drugs and stem cell therapies gaining popularity among physicians and patients alike. Major players in the multiple myeloma therapeutics market are accelerating product launches and clinical trials with partnerships, collaborations, and outsourcing among various start-ups.
The increasing number of drug approvals, mainly monoclonal antibodies and corticosteroids, used to treat multiple myeloma is projected to drive the growth of the MEA multiple myeloma therapeutics market. Studies have shown that cytolytic antibody directed against CD38 is effective for treating multiple myeloma in adult patients. The development of new innovative products and combination therapies for multiple myeloma is becoming a significant factor contributing to the growth of this market in the near future.
Moreover, several technological advancements, such as the development of microRNA therapies and nanomedicines, are also used as growth factors that can facilitate the delivery of macromolecular agents to the bone marrow and catalyze antitumor responses. All these aforementioned factors will provide ample growth opportunities for the MEA multiple myeloma therapeutics market during the forecast period.
On the other hand, several factors such as the high cost of treatment and limited target population of patients may hinder the growth of the MEA multiple myeloma therapeutics market. In addition, the equipment and products needed for therapies such as chemotherapy and radiotherapy are required skilled professionals and well-equipped medical facilities, which cannot be seen in emerging economies in the region due to poor healthcare infrastructure. Apart from this, the lower number of people with severe multiple myeloma showing symptoms and requiring treatment is estimated to be another factor responsible for limiting the market's growth during the forecast period.
This research report on the MEA multiple myeloma therapeutics market has been segmented and sub-segmented into the following categories
By Treatment Type:
By Drug Type:
During the forecast period, the Saudi Arabian market is projected to hold the largest share in the MEA multiple myeloma therapeutics market due to driving factors such as high awareness associated with early diagnosis and treatment of cancer, supportive policies reimbursement, and the development of healthcare infrastructure. According to the WHO country listing, multiple myeloma and lymphoma accounted for between 9.62% and 11% cancer-related deaths. According to the 2014 Saudi Cancer Registry, multiple myeloma had accounted for 1% of all cancer cases, with an incidence of 1% in men and 0.7% in women.
The United Arab Emirates dominates the studied market due to faster approval rates, better healthcare facilities, favorable healthcare policies, and significant players in this region. In addition, the growing awareness associated with a cancer diagnosis and the development of healthcare infrastructure responsible for the wide accessibility of modern technology will drive the regional market.
Improving healthcare reimbursement policies and the high probability of occurring in the elderly population will be responsible for growing the African regional market.
KEY MARKET PLAYERS:
Companies playing a vital role in the MEA multiple myeloma therapeutics market profiled in this report are AB Science SA, AbbVie Inc., Ablynx NV, Acceleron Pharma Inc., IGF Oncology LLC., ImmunGene Inc., Millennium Pharmaceuticals Inc., MimiVax LLC, Mirna Therapeutics, RedHill Biopharma Ltd., Rhizen Pharmaceuticals S.A., Terpenoid Therapeutics Inc., Teva Pharmaceutical Industries Ltd., TG Therapeutics Inc., and Johnson and Johnson.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Treatment Type
126.96.36.199 Anthracycline antibiotic
188.8.131.52 Alkylating agent
5.1.2 Targeted Therapy
184.108.40.206 Proteasome inhibitor
5.2 By Drug Type
220.127.116.11 Dexamethasone (Decadron)
18.104.22.168 Prednisone (Deltasone/Orasone)
5.2.2 Immunomodulatory agents
22.214.171.124 Thalidomide (Thalomid)
126.96.36.199 Lenalidomide (Revlimid)
188.8.131.52 Arsenic trioxide (Trisenox)
184.108.40.206 Plerixafor (Mozobil)
6. Geographical Analysis
7. Pipeline Product Analysis
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials (by Stage of Development, Indication, Molecule Type and Molecular Target)
7.4.1 Failure Rate
7.4.2 Clinical Trial Duration
7.4.3 Clinical Trial Size
8. Strategic Analysis
8.1 PESTLE analysis
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9. Market Leaders' Analysis
9.1 AB Science SA
9.1.2 Product Analysis
9.1.3 Strategic Evaluation and Operations
9.1.4 Financial analysis
9.1.5 Legal issues
9.1.6 Recent Developments
9.1.7 SWOT analysis
9.1.8 Analyst View
9.2 AbbVie Inc.
9.3 Ablynx NV
9.4 Acceleron Pharma Inc.
9.5 IGF Oncology LLC.
9.6 ImmunGene Inc.
9.7 Millennium Pharmaceuticals Inc.
9.8 MimiVax LLC
9.9 Mirna Therapeutics
9.10 RedHill Biopharma Ltd.
9.11 Rhizen Pharmaceuticals S.A.
9.12 Terpenoid Therapeutics Inc.
10. Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11. Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
a) List of Tables
b) List of Figures
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.